Skip to main content

Month: February 2022

Grapefruit USA, Inc. CEO Elected to Coachillin’ Canna-Business Park Board of Directors

LOS ANGELES and DESERT HOT SPRINGS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Grapefruit USA, Inc. (OTCQB: GPFT) (“Grapefruit” or the “Company”), an innovative California-based cannabiotech company, today announces that its Chief Executive Officer Bradley J. Yourist has been elected to the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park’s Property Owners Association Board of Directors (the “Board”) for a one-year term, effective immediately. The 160-acre Coachillin’ Canna-Business Park (the “Park”), located in Desert Hot Springs, California, 14 miles north of downtown Palm Springs, is the first and largest cooperative canna-business compound of its kind. It is unique in that the landowners each own a proportionate interest in a collaborative owner’s association, which allows them...

Continue reading

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 60 days following the presentation. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two...

Continue reading

G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

– Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA™ (trilaciclib) – – Completed Hiring, Training, and Deployment of G1’s COSELA Sales Team – – Announced That Initial Results from Phase 3 Trial of Trilaciclib in Colorectal Cancer (PRESERVE 1) Are Now Expected Early in the First Quarter of 2023 – – Initiated Two New Phase 2 Trials to Confirm the Immune-Based Mechanism of Action (MOA) of Trilaciclib and to Help Clarify the Potential Synergistic Effects of Trilaciclib and an Antibody-Drug Conjugate (ADC) – – Management to Host Webcast and Conference Call today at 8:30 AM ET – RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage...

Continue reading

Parsons Reports Fourth Quarter and Full Year 2021 Results

Q4 2021 Financial HighlightsRevenue of $951 million in the quarter and $1.9 billion in the second half of 2021, representing total and organic growth of 9% and 7% over the first half of 2021, respectively Net income of $29 million Adjusted EBITDA of $91 million and margin of 9.6% Cash flow from operations of $90 million for the fourth quarter Book-to-bill ratio of 0.9x in Q4 2021 and 1.25x for fiscal year 2021 Total backlog of $8.3 billion, a 3% year-over-year increaseStrategic HighlightsAll metrics at or above full-year 2021 guidance mid-point ranges Won three contracts each worth approximately $100 million or more in Q4, including the $2 billion Faro Mine award, one of the largest in the company’s history Strong year for ESG performance; enhancing all three ESG categories Establishing fiscal year 2022 guidanceCENTREVILLE, Va.,...

Continue reading

Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to the grantee’s acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the grantee’s employment compensation in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of non-statutory stock option awards to individuals who were not previously employees of Liquidia (or following a bona fide period of non-employment), as an inducement material to such individual’s entering...

Continue reading

Kinross Russia mines operating according to plan, unaffected by sanctions

TORONTO, Feb. 23, 2022 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) (the “Company”) announced today that its operations in Russia are operating according to plan and currently remain unaffected by U.S. sanctions announced on February 22, 2022. Kinross has successfully operated in Russia for more than 25 years and has previously managed through similar situations while complying with applicable laws. The Company has diversified procurement and logistics structures in Russia, with the majority of its procurement coming from within the country. Approximately 98% of the employees of Kinross’ Russian subsidiaries are Russian locals, and given the ice road supply season, its operations have a full year of supplies on hand. Kinross refines gold produced from its Russian mines in-country and retains flexibility to sell...

Continue reading

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions WAYNE, Pa., Feb. 23, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for its specialty catheters and coronary guidewires for use in crossing chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs are longstanding complete blockages in coronary arteries that result in profound regional reduction of coronary blood flow (ischemia). Importantly, clinically significant CTOs are found in nearly 20% of patients undergoing diagnostic coronary angiography for...

Continue reading

K92 Mining Reports Significant Resource Upgrade at High-Grade Kora Deposit and Maiden Judd Resource Estimate

Figure 1 Kora Resource Lode WireframesFigure 2 K1 and K2 Resource Long Section by Resource CategoryFigure 3 K1 Resource Long SectionFigure 4 K2 Resource Long SectionFigure 5 Kora Resource Cut-Grade vs Ounces and Tonnage CurveFigure 6 Judd Resource Lode Wireframe Long SectionFigure 7 J1 Resource Long Section by Resource CategoryFigure 8 J1 Vein Long SectionFigure 9 Judd Resource Cut-Grade vs Ounces and Tonnage CurveFigure 10 Near Mine Exploration TargetsVANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQB: KNTNF) is pleased to announce results from the updated resource estimate completed on the Kora deposit and the maiden resource for the Judd deposit, at its producing Kainantu Gold Mine in Papua New Guinea. The resource estimate is...

Continue reading

Q3, 2021/22

To Nasdaq OMX Copenhagen A/S Public announcement no. 514 February 23rd, 2022ECONOMIC KEY FIGURES FOR GLUNZ & JENSEN HOLDING A/S Q3 2021/22 The Q3, 2021/22 of the fiscal year was reviewed and approved at the Board of Directors meeting today. The Board of Directors announces the following consolidated financial statements year to date (YTD) for Q3 (the first 9 months) of 2021/22. The Q3 result of the fiscal year 2021/22 has exceeded the expectations under difficult market conditions. HighlightsThe revenue for YTD Q3 2021/22 amounted to DKK 112,9 million (2020/21: DKK 104,2 million). The process of strengthening earnings by streamlining and consolidating production and supply chain at the subsidiary in Slovakia is following the outlined plan and is close to being finalized. EBITDA for the period was DKK 19,1 million (2020/21:...

Continue reading

CAAC Formally Adopts Special Conditions for EH216-S AAV Type Certification

GUANGZHOU, China, Feb. 23, 2022 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company, today announced that the Civil Aviation Administration of China (“CAAC”) has formally adopted the Special Conditions for EH216-S1 AAV Type Certification (the “Special Conditions”), which was effective on February 9th, 2022 and published on the CAAC website on February 22th, 2022. The Special Conditions provides EHang with basis for compliance and safety of EH216-S AAVs, including flight performance, structures, design and constructions, propulsion systems, systems and equipment, data link and ground control station. The Company expects to deploy the EH216-S unmanned aircraft system in low-altitude passenger-carrying commercial...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.